Skanska announced that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct. The order reduction amounts to USD 49 million, about SEK 510 million, which will be deducted from the US order bookings for the first quarter 2024. The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215 million, about SEK 2.2 billion, and was announced August 4, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
193.2 SEK | -1.23% | -0.13% | +5.92% |
06-25 | Skanska Sells Sweden Office Building to Internal Portfolio for SEK2.5 Billion | MT |
06-25 | Skanska Sells Planned Court Building in Sweden for SEK490 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.92% | 7.54B | |
-10.73% | 62.21B | |
+2.13% | 59.1B | |
+26.49% | 39.96B | |
+13.93% | 31.41B | |
+10.96% | 28.67B | |
+13.73% | 20.62B | |
+13.38% | 19.23B | |
+75.71% | 17.79B | |
+35.92% | 17.08B |
- Stock Market
- Equities
- SKA B Stock
- News Skanska AB
- Skanska Announces Decreased Scope for Facility in Everett, Washington, USA, Worth USD 49 Million, About SEK 510 Million